Takeda Pharmaceutical Company Enhances Maternal and Child Nutrition Through Indonesia's CINTA Program
- Takeda Pharmaceutical Company funds the CINTA program to improve maternal and child nutrition in Indonesia over five years.
- The initiative trains nearly one million health workers in climate-responsive nutrition interventions for vulnerable populations.
- Takeda's collaboration with Vitamin Angels aims to create sustainable health solutions and enhance corporate social responsibility efforts.
Takeda Pharmaceutical Company Commits to Enhancing Maternal and Child Nutrition in Indonesia
Takeda Pharmaceutical Company Limited takes a significant step in global health by funding the Climate-Inspired Nutrition Through Action (CINTA) program, launched by Vitamin Angels during a United Nations General Assembly side event on September 23, 2025. This ambitious five-year initiative aims to tackle Indonesia’s pressing nutrition challenges, where over 30% of children under five suffer from stunting and nearly one-third of women of reproductive age experience anemia. The CINTA program is designed to provide targeted nutrition solutions to the most vulnerable populations, focusing particularly on women and children, who are disproportionately affected by these health issues.
Under the CINTA initiative, nearly one million health workers will receive training to deliver climate-responsive nutrition interventions. These interventions include multiple micronutrient and vitamin A supplementation, deworming treatments, breastfeeding support, and essential nutrition education. By addressing these critical areas, the program not only aims to improve immediate health outcomes but also to build a resilient healthcare system capable of withstanding the adverse effects of climate change. Indonesia ranks 46 out of 163 on UNICEF's Children's Climate Risk Index, highlighting the urgent need for such comprehensive health strategies in the face of escalating climate-related vulnerabilities.
Toshie Ando, Head of Global CSR & Partnership Strategy at Takeda, underscores the company's long-term commitment to fostering climate-resilient health solutions. The CINTA program also emphasizes strengthening supply chains to enable sustainable local production of nutrition supplies, which is vital for ensuring that these interventions are both effective and enduring. With Takeda’s support, Vitamin Angels aims to expand its reach across Indonesia, leveraging strategic partnerships and technical expertise to create lasting improvements in maternal and child health.
In addition to its focus on nutrition, the CINTA program aligns with broader global efforts to combat the health impacts of climate change. Dr. Ana Céspedes, CEO of Vitamin Angels, emphasizes the necessity of preventing vulnerable populations from experiencing adverse health consequences due to environmental factors. The collaboration between Takeda and Vitamin Angels signals a proactive approach to addressing both nutrition and climate issues, thereby fostering a healthier future for generations in Indonesia.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

